Literature DB >> 21247548

Subclinical and clinical correlates of left ventricular wall motion abnormalities in the community.

Connie W Tsao1, Philimon Gona, Carol Salton, Peter G Danias, Susan Blease, Udo Hoffmann, Caroline S Fox, Mark Albert, Daniel Levy, Christopher J O'Donnell, Warren J Manning, Susan B Yeon.   

Abstract

The prevalence and clinical correlates of left ventricular (LV) wall motion abnormalities (WMAs), associated with morbidity and mortality, have not been well-characterized in the population. Framingham Heart Study Offspring Cohort participants (n = 1,794, 844 men, age 65 ± 9 years) underwent cine cardiovascular magnetic resonance for evaluation of LV function. A subset (n = 1,009, 460 men) underwent cardiac multidetector computed tomography for analysis of coronary artery calcium. The presence of coronary heart disease and heart failure (CHD-HF) were assessed in relation to the presence of WMAs. WMAs were present in 117 participants (6.5%) and were associated with male gender, elevated hemoglobin A1c, LV mass, LV end-diastolic volume, and lower LV ejection fraction. Of the 1,637 participants without CHD-HF, 68 (4.2%) had WMAs. In this group, WMAs were associated with obesity, hypertension, and Framingham coronary heart disease risk score in the age- and gender-adjusted analyses and were associated with male gender and hypertension on multivariate analysis. Most subjects with WMAs were in the greatest coronary artery calcium groups. The presence of coronary artery calcium greater than the seventy-fifth percentile and Agatston score >100 were associated with a greater than twofold risk of WMAs in the age- and gender-adjusted analysis but were no longer significant when additionally adjusted for CHD-HF. Previous Q-wave myocardial infarction was present in 29% of the 117 participants with WMAs. In conclusion, in the present longitudinally followed free-living population, 4.2% of the participants without CHD-HF had WMAs. WMAs were associated with the clinical parameters associated with cardiovascular disease risk. Aggressive risk factor modification may be prudent for subjects with WMAs, particularly those free of clinical CHD-HF.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21247548      PMCID: PMC3233992          DOI: 10.1016/j.amjcard.2010.11.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.

Authors:  Olga Vaccaro; Lynn E Eberly; James D Neaton; Lingfeng Yang; Gabriele Riccardi; Jeremiah Stamler
Journal:  Arch Intern Med       Date:  2004-07-12

3.  Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study.

Authors:  S H Jee; I Suh; I S Kim; L J Appel
Journal:  JAMA       Date:  1999-12-08       Impact factor: 56.272

4.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

5.  Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension.

Authors:  G de Simone; V Palmieri; M J Koren; G A Mensah; M J Roman; R B Devereux
Journal:  J Hypertens       Date:  2001-01       Impact factor: 4.844

6.  Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.

Authors:  S D Solomon; R J Glynn; S Greaves; U Ajani; J L Rouleau; F Menapace; J M Arnold; C Hennekens; M A Pfeffer
Journal:  Ann Intern Med       Date:  2001-03-20       Impact factor: 25.391

7.  Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group.

Authors:  Charlotte Ebeling Barbier; Tomas Bjerner; Lars Johansson; Lars Lind; Håkan Ahlström
Journal:  J Am Coll Cardiol       Date:  2006-07-24       Impact factor: 24.094

8.  Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort.

Authors:  Carol J Salton; Michael L Chuang; Christopher J O'Donnell; Michelle J Kupka; Martin G Larson; Kraig V Kissinger; Robert R Edelman; Daniel Levy; Warren J Manning
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

9.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.

Authors:  D J Lerner; W B Kannel
Journal:  Am Heart J       Date:  1986-02       Impact factor: 4.749

10.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

View more
  2 in total

1.  Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort.

Authors:  Susan B Yeon; Carol J Salton; Philimon Gona; Michael L Chuang; Susan J Blease; Yuchi Han; Connie W Tsao; Peter G Danias; Daniel Levy; Christopher J O'Donnell; Warren J Manning
Journal:  J Magn Reson Imaging       Date:  2014-05-12       Impact factor: 4.813

Review 2.  70-year legacy of the Framingham Heart Study.

Authors:  Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2019-11       Impact factor: 32.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.